JP2020502248A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502248A5
JP2020502248A5 JP2019534685A JP2019534685A JP2020502248A5 JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5 JP 2019534685 A JP2019534685 A JP 2019534685A JP 2019534685 A JP2019534685 A JP 2019534685A JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
preparation according
treating
compound
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019534685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502248A (ja
JP7117306B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031836 external-priority patent/WO2018118109A1/en
Publication of JP2020502248A publication Critical patent/JP2020502248A/ja
Publication of JP2020502248A5 publication Critical patent/JP2020502248A5/ja
Priority to JP2022105969A priority Critical patent/JP7461414B2/ja
Application granted granted Critical
Publication of JP7117306B2 publication Critical patent/JP7117306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019534685A 2016-12-21 2017-05-09 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物 Active JP7117306B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105969A JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437181P 2016-12-21 2016-12-21
US62/437,181 2016-12-21
PCT/US2017/031836 WO2018118109A1 (en) 2016-12-21 2017-05-09 Rho kinase inhibitor ba-1049 (r) and active metabolites thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105969A Division JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Publications (3)

Publication Number Publication Date
JP2020502248A JP2020502248A (ja) 2020-01-23
JP2020502248A5 true JP2020502248A5 (enExample) 2020-06-18
JP7117306B2 JP7117306B2 (ja) 2022-08-12

Family

ID=62627011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534685A Active JP7117306B2 (ja) 2016-12-21 2017-05-09 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物
JP2022105969A Active JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105969A Active JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Country Status (8)

Country Link
EP (2) EP4509138A3 (enExample)
JP (2) JP7117306B2 (enExample)
DK (1) DK3558314T3 (enExample)
ES (1) ES3002432T3 (enExample)
FI (1) FI3558314T3 (enExample)
PL (1) PL3558314T3 (enExample)
PT (1) PT3558314T (enExample)
WO (1) WO2018118109A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
FI3558314T3 (fi) * 2016-12-21 2024-11-29 Bioaxone Biosciences Inc Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
DK3877364T3 (da) * 2018-11-06 2024-09-23 Cervello Therapeutics LLC Rock-kinasehæmmere
US12253482B2 (en) 2019-11-01 2025-03-18 Kirin Holdings Kabushiki Kaisha Method for determining structure of substance in multicomponent sample
JP7213839B2 (ja) * 2019-11-21 2023-01-27 キリンホールディングス株式会社 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法
EP4063839A4 (en) * 2019-11-21 2023-11-22 Kirin Holdings Kabushiki Kaisha METHOD FOR PREPARING A CRYSTAL STRUCTURAL ANALYSIS SAMPLE FOR STRUCTURAL ANALYSIS USING A CRYSTAL SPONGE METHOD
WO2023060820A1 (zh) * 2021-10-15 2023-04-20 合肥中科普瑞昇生物医药科技有限公司 胃癌原代细胞的培养基和培养方法
US20250000083A1 (en) 2021-11-11 2025-01-02 The Doshisha Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014783A1 (en) * 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2005080394A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
JP4652112B2 (ja) 2005-04-26 2011-03-16 富士フイルム株式会社 投射型表示装置
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
CA2731095A1 (en) 2008-08-05 2010-02-11 Abbott Laboratories Compounds useful as inhibitors of protein kinases
WO2012170554A1 (en) 2011-06-06 2012-12-13 Theodore Mark Kamenecka N-biphenylmethylindole modulators of pparg
MX384910B (es) * 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
JP6581111B2 (ja) * 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Rhoキナーゼ阻害剤としてのイソキノリンスルホン誘導体
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
US9687483B2 (en) 2015-01-26 2017-06-27 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors
FI3558314T3 (fi) 2016-12-21 2024-11-29 Bioaxone Biosciences Inc Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita

Similar Documents

Publication Publication Date Title
JP2017514910A5 (enExample)
FI3558314T3 (fi) Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita
JP2022540935A5 (enExample)
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
JP2014221779A5 (enExample)
EP3471660A4 (en) MEDICAL DEVICE FOR THE TREATMENT OF VASCULATORS
JP2017506627A5 (enExample)
JP2015513557A5 (enExample)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2017090039A3 (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
EP3412668A3 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
JP2017517565A5 (enExample)
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EP3419981A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
MX2020012336A (es) Formulacion farmaceutica.
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
JP2016540015A5 (enExample)
PH12015501793B1 (en) Bicyclic compounds
WO2015001541A3 (en) Pharmaceutical film composition
WO2017105881A8 (en) Deuterated compounds for treating pain
LT3124048T (lt) Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui
MX2017005586A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas.
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)